Evolent Health (NYSE:EVH) Price Target Lowered to $5.00 at UBS Group

Evolent Health (NYSE:EVH) had its target price trimmed by UBS Group from $10.00 to $5.00 in a research report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the technology company’s stock.

A number of other analysts have also issued reports on EVH. BMO Capital Markets reissued an “outperform” rating and issued a $3.50 price target on shares of Evolent Health in a research note on Wednesday. BTIG Research dropped their price target on shares of Evolent Health from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. decreased their target price on Evolent Health from $13.00 to $7.00 and set an “overweight” rating for the company in a research note on Monday, November 17th. Royal Bank Of Canada lowered their price objective on shares of Evolent Health from $5.00 to $3.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Finally, Citizens Jmp decreased their price target on Evolent Health from $11.00 to $10.00 and set a “market outperform” rating for the company in a research note on Tuesday, January 6th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Evolent Health currently has a consensus rating of “Moderate Buy” and an average target price of $6.50.

Evolent Health Price Performance

Shares of NYSE:EVH opened at $3.33 on Thursday. Evolent Health has a 12 month low of $2.50 and a 12 month high of $12.06. The firm has a market capitalization of $371.63 million, a price-to-earnings ratio of -0.65 and a beta of 0.27. The business’s 50 day simple moving average is $3.50 and its 200-day simple moving average is $5.84. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.33 and a quick ratio of 1.33.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.30%. The business had revenue of $468.72 million for the quarter, compared to analyst estimates of $468.48 million. During the same period in the previous year, the firm earned ($0.02) EPS. The business’s revenue for the quarter was down 27.5% compared to the same quarter last year. As a group, equities analysts forecast that Evolent Health will post 0.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evolent Health

Several institutional investors and hedge funds have recently made changes to their positions in EVH. Vanguard Group Inc. boosted its holdings in Evolent Health by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,966,830 shares of the technology company’s stock valued at $92,779,000 after purchasing an additional 45,299 shares during the period. Durable Capital Partners LP acquired a new position in Evolent Health during the 2nd quarter worth about $72,326,000. Eventide Asset Management LLC boosted its stake in shares of Evolent Health by 54.0% in the 3rd quarter. Eventide Asset Management LLC now owns 6,292,511 shares of the technology company’s stock valued at $53,246,000 after purchasing an additional 2,205,659 shares during the last quarter. Engaged Capital LLC lifted its stake in shares of Evolent Health by 13.0% in the 2nd quarter. Engaged Capital LLC now owns 5,854,468 shares of the technology company’s stock valued at $65,921,000 after purchasing an additional 675,000 shares during the period. Finally, Rubicon Founders LLC bought a new stake in shares of Evolent Health in the 3rd quarter valued at $49,204,000.

Key Stories Impacting Evolent Health

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 earnings beat — Evolent posted $0.08 EPS vs. consensus $0.06, turning profitable year-over-year and giving investors a near-term catalyst. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Management to participate in investor conferences with live webcasts — increases visibility and gives investors direct access to management’s strategy and outlook. Evolent to Participate in Upcoming Investor Conferences
• Positive Sentiment: Some analysts maintain buy ratings and still show upside — BTIG (new $8 PT) and UBS (new $5 PT) kept buy calls, signaling continued institutional conviction despite lower targets. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Neutral Sentiment: Market commentary and analysis highlight turnaround potential and technical momentum — pieces noting EVH as “cheap, levered, but ready to rebound” and coverage of the intraday move provide narrative context rather than new fundamentals. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Investor note/roundups covering the share move summarize news flow for traders but don’t add new company data. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Negative Sentiment: Multiple price-target cuts and a downgrade — several firms lowered PTs (Needham, Citi, RBC, UBS) and KeyCorp downgraded EVH to sector weight, which increases near-term downside risk and reflects investor concerns about top-line declines and leverage. Benzinga coverage of analyst actions
• Negative Sentiment: Revenue decline and margin pressure remain issues — revenue was roughly flat to consensus but down year-over-year, and the company still reports negative net margins, which could limit investor enthusiasm absent clear margin improvement. Evolent Health, Inc. Q4 2025 Earnings Call Transcript

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.